Press Releases FibroGen, Inc.

Equities

FGEN

US31572Q8087

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
1.2 ^USD	+4.35%		-7.69%	+35.39%

May. 23	FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting	CI
May. 07	Top Premarket Gainers	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting	May. 23	AQ
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS	May. 08	AQ
FibroGen : Corporate Presentation – May 2024	May. 07	PU
FibroGen to Participate in Upcoming Investor Conferences	May. 07	AQ
FibroGen: Q1 Earnings Snapshot	May. 06	AQ
FibroGen Reports First Quarter 2024 Financial Results	May. 06	AQ
FibroGen to Report First Quarter 2024 Financial Results	Apr. 29	AQ
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	AQ
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer	Apr. 02	AQ
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference	Mar. 26	AQ
FibroGen : Corporate Presentation – March 2024	Mar. 19	PU
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer	Mar. 11	AQ
FibroGen : Corporate Presentation – March 2024	Mar. 06	PU
FibroGen: Q4 Earnings Snapshot	Feb. 26	AQ
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 26	AQ
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea	Feb. 26	AQ
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results	Feb. 20	AQ
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024	Feb. 05	AQ
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer	Jan. 25	AQ
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	Dec. 26	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases FibroGen, Inc.

Equities

FGEN

US31572Q8087

Press Releases

Filters